Published 2 years ago • loading... • Updated 2 years ago

Experimental vaccine against Marburg virus shows promise in first-in-human clinical trial

Summary by Ground News

A paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), could someday be an important tool to respond to MARV outbreaks. MARV is a filovirus in the same family as Ebola virus.

5 Articles

All

Left

Center

Right

Big News Network

Lean Left

Marburg vaccine shows promising results in first-in-human study

The Marburg virus (MARV) experimental vaccine was safe and elicited an immunological response in a tiny, first-in-human clinical study, according to a recently

2 years ago

Read Full Article

News Medical

Center

Experimental vaccine against Marburg virus shows promise in first-in-human clinical trial

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

2 years ago·United States

Read Full Article

Science Daily

Center

Marburg vaccine shows promising results in first-in-human study

A new article shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine could someday be an important tool to respond to Marburg virus outbreaks.

2 years ago·United States

Read Full Article

Medical Xpress

Center

Marburg virus vaccine shows promising results in first-in-human study

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers ...

2 years ago

Read Full Article